Hemispherx Biopharma Renews Sales, Marketing, Distribution and Supply Agreement with GP Pharm

by Barry101 | May 31, 2016 | Press Release

Initial Target is ANMAT Approval to Treat Chronic Fatigue Syndrome Patients in ArgentinaPHILADELPHIA, May 31, 2016 — Hemispherx Biopharma. Inc. (NYSE MKT:HEB) announced today that it executed a renewed Sales, Marketing, Distribution and Supply Agreement for...

UPDATE — Hemispherx Amends and Restates Agreement with myTomorrows for the Early Access Program for Rintatolimod in Europe

by Barry101 | May 24, 2016 | Press Release

PHILADELPHIA, May 24, 2016 — Hemispherx Biopharma (NYSE MKT:HEB) announced today that it has executed an amended and restated agreement with Impatients, N.V., a Netherlands based company doing business as myTomorrows, for the commencement and management of an...

Hemispherx Amends and Restates Agreement with myTomorrows for the Early Access Program for Rintatolimod in Europe

by Barry101 | May 23, 2016 | Press Release

PHILADELPHIA, May 23, 2016 — Hemispherx Biopharma (NYSE MKT:HEB) announced today that it has executed an amended and restated agreement with Impatients, N.V., a Netherlands based company doing business as myTomorrows, for the commencement and management of an...

Hemispherx Biopharma Announces Financial Results for the Three Months Ended March 31, 2016

by Barry101 | May 16, 2016 | Press Release

The company is now focusing on commercial success by seeking co-development partners and working closely with the research and regulatory communities to bring disease fighting technologies to the world.Conference Call Scheduled for Tuesday, May 17, 2016 at 1:00 PM...

Hemispherx Biopharma Announces Conference Call to Provide Quarterly Business Update on May 17, 2016

by Barry101 | May 12, 2016 | Press Release

PHILADELPHIA, May 12, 2016 — Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the “Company” or “Hemispherx”) announced today that it anticipates filing its 2016 first quarter financial results for quarter ended March 31 on Monday, May 16,...

Hemispherx Biopharma Retains Huron Consulting Group to Support Partnering Strategy and Planning for Alferon® and Ampligen®

by Barry101 | Apr 20, 2016 | Press Release

PHILADELPHIA, April 20, 2016 — Hemispherx Biopharma (NYSE MKT:HEB) (the “Company” or “Hemispherx”) announced that it has signed a consulting agreement with Huron Consulting Group, a global consultancy with decades of experience in the...